FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of March, 2004
Commission File Number: 1-10817
CELLTECH GROUP PLC
(Translation of registrant's name into English)
208 Bath Road, Slough, Berkshire SL1 3WE ENGLAND
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
(If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________).
Enclosure 1: Holding(s) in Company announcement dated 16 March 2004
Enclosure 2: Holding(s) in Company announcement dated 22 March 2004
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Celltech Group plc
2. Name of shareholder having a major interest
AMVESCAP PLC as agent for the ICVC named below.
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
INVESCO Perpetual UK Investment Series
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
Unknown
5. Number of shares / amount of stock acquired
250,000
6. Percentage of issued class
0.09%
7. Number of shares / amount of stock disposed
N/a
8. Percentage of issued class
N/a
9. Class of security
Ordinary 50p shares
10. Date of transaction
12 March 2004
11. Date company informed
16 March 2004
12. Total holding following this notification
28,005,327
13. Total percentage holding of issued class following this notification
10.08%
14. Any additional information
This holding is included in the overall holding of 15.15% disclosed by
AMVESCAP on 23 February 2004.
15. Name of contact and telephone number for queries
Anita Dowling Tel. 01753 777106
16. Name and signature of authorised company official responsible for making
this notification
J A D Slater
Date of notification
16 March 2004
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Celltech Group plc
2. Name of shareholder having a major interest
FMR Corp and its direct and indirect subsidiaries and Fidelity
International Limited (FIL) and its direct and indirect subsidiaries
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
Non-beneficial holder
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
| State Street Nominees Limited | 527,612 | ||
| Chase Nominees Limited | 2,800,978 | ||
| State Street Bank & Trust Company | 437,100 | ||
| HSBC | 258,300 | ||
| Bank of New York | 2,500 | ||
| Chase Nominees Ltd | 23,600 | ||
| State Street Bank & Trust | 215,822 | ||
| State Street Nominees Ltd | 56,810 | ||
| Lloyds Bank Nominees Limited | 346,800 | ||
| Brown Brothers Harriman | 12,900 | ||
| JP Morgan Chase | 105,000 | ||
| Northern Trust | 61,700 | ||
| Morgan Stanley & Co | 44,400 | ||
| Chase Nominees | 14,507,583 | ||
| Chase Manhattan Bank London | 1,678,990 | ||
| HSBC Client Holdings Nominee (UK) Limited | 196,500 | ||
| Deutsche Bank | 15,000 | ||
| Citibank | 277,300 | ||
| HSBC | 125,814 | ||
| Bank of New York London | 259,100 | ||
| Chase Nominees Ltd | 144,300 | ||
| Northern Trust | 71,700 | ||
| Chase Nominees | 1,230,080 | ||
| Nortrust Nominees Ltd | 826,926 | ||
| HSBC Client Holdings Nominee (UK) Limited | 2,578,974 | ||
| Chase Manhattan Bank London | 752,648 | ||
| Northern Trust | 1,176,300 | ||
| JP Morgan | 739,311 | ||
| Bank of New York London | 1,280,600 | ||
| Morgan Stanley | 398,600 | ||
| Deutsche Bank | 337,735 | ||
| Mellon Nominees Ltd | 33,700 | ||
| State Street Nominees Ltd | 337,300 | ||
| Bank of New York Brussels | 534,041 | ||
| State Street Bank & Trust | 429,879 | ||
| National Australia Bank | 8,600 | ||
| PICG | 4,400 | ||
| Chase Manhattan Bank AG Frankfurt | 81,655 | ||
| Citibank | 146,300 | ||
| J P Morgan | 23,700 | ||
| State Street Hong Kong | 10,600 | ||
| Bankers Trust | 58,900 | ||
| Clydesdale Bank (Head Office) Nominees Limited | 205,300 | ||
| HSBC Client Holdings Nominee (UK) Limited | 200 | ||
5. Number of shares / amount of stock acquired
2,447,721 (since last notification)
6. Percentage of issued class
0.88%
7. Number of shares / amount of stock disposed
N/A
8. Percentage of issued class
N/A
9. Class of security
50p Ordinary Shares
10. Date of transaction
22 March 2004
11. Date company informed
22 March 2004
12. Total holding following this notification
33,365,558
13. Total percentage holding of issued class following this notification
12.01%
14. Any additional information
15. Name of contact and telephone number for queries
Cheryl Cramer Tel: 01753 447933
16. Name and signature of authorised company official responsible for making
this notification
J A D Slater
Date of notification
22 March 2004
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CELLTECH
GROUP PLC
(Registrant)
By: /s/
PETER ALLEN
Peter
Allen
Chief
Financial Officer
Dated: 29 March, 2004